Private Equity Archives - Page 6 of 6 - Gilde Healthcare

Menu
Menu
Home

Neuigkeiten & Einblicke
Private Equity

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to be ‘the scientific partner of choice for biomarker and bioanalytical solutions’. Alderley Analytical’s CRO services complement Synexa Life Sciences’ established capabilities...
3. Oktober 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

test Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in the healthcare market. Strengthening their joint position will further elevate service levels and product offerings of both companies. The combination […]

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

test Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next Generation Infrastructure Fund I unterzeichnet. Gilde Healthcare investierte in RAD-x und gründete das Unternehmen gemeinsam mit dem Management im Jahr […]

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and...

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld as Chairman

The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology....

Swiss Dental Solutions AG und Gilde Healthcare formen langfristige Partnerschaft zur Beschleunigung des Wachstums

Swiss Dental Solutions AG (“SDS“) gab heute bekannt, dass Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare“), ein spezialisierter Healthcare-Investor, die Mehrheit der Aktien an der SDS über die UNAC Holding AG als Teil eines internationalen Wachstums- und Expansionsplans übernimmt. Dr. Karl Ulrich Volz bleibt weiterhin eng mit...

Swiss Dental Solutions AG partners with Gilde Healthcare to accelerate growth in the emerging ceramic dental implant markets

Swiss Dental Solutions AG (“SDS”) today announced that Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has come to an agreement to acquire a majority of the shareholding of SDS through UNAC Holding AG as part of an international operational growth and development plan....

Gilde Healthcare investiert in Koscher & Würtz, einen deutschen Auftragshersteller für chirurgische Präzisionsinstrumente

Nachdem Gilde Healthcare vor weniger als 18 Monaten in Chr. Diener investiert hat, ist die Akquisition von Koscher & Würtz (K&W) ein wichtiger Schritt in der Bildung einer Gruppe von führenden Auftragsherstellern chirurgischer Instrumente. K&W wird zukünftig in der Gruppe neben Chr. Diener tätig sein und gemeinsam...

Gilde Healthcare company Noema Pharma raises CHF 103 million ($112 million)

Gilde Healthcare, a leading specialized healthcare investor, today announced that its portfolio company Noema Pharma, has raised an oversubscribed CHF 103 million ($112 million) Series B financing round from new and existing investors. Noema Pharma is a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders....
Loading...
These were all messages
c878d23eb4